Imaging Dopamine Function and Its Impact on Outcome After Traumatic Brain Injury (TBI)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Change in Disability Rating Scale [ Time Frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks ]
The primary outcome measure will be the change in Disability Rating Scale over 4 weeks. The Disability Rating Scale is a commonly used and reliable instrument for monitoring minor changes occurring throughout the course of a patient's recovery (Rappaport et al., 1982).
Secondary Outcome Measures :
John F Kennedy Coma Recovery Scale Revised [ Time Frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Traumatic Brain Injury patients in Inpatient Rehabilitation
Age between 18-50 years old
Admitted to a North Texas TBI Model Systems-affiliated rehabilitation facility within 16 weeks of injury
Rated at Rancho VI Los Amigos Levels of Cognitive Functioning Scale of less than or equal to Stage V at the time of enrollment
Disability Rating Scale total score >/= 7
Central Nervous System disorder resulting in functional disability predating TBI
Documented diagnosis of disease processes impacted by the dopamine system (e.g., Parkinson's Disease, clinician diagnosed Attention Deficit Hyperactivity Disorder, substance abuse/dependence (excluding marijuana, alcohol, tobacco), or schizophrenia)
Pre-injury use of dopaminergic pharmaceuticals (i.e., methylphenidate, amantadine, or dopamine receptor blockers such as olanzapine or quetiapine)
Documented contraindication to use of methylphenidate including allergy
Medical condition not compatible with use of Methylphenidate
Recent diagnosis or therapeutic study using radiopharmaceuticals